[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nstemi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nstemi":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,77,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100619319","efficacy-of-immediate-versus-staged-complete-revascularization-in-patients-with-nste-acs-and-multivessel-disease-future-ii-100619319",false,"NCT07343076","Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)","Inclusion Criteria:\n\n1. Age: 18 years or older.\n2. Patients with intermediate-to-high risk NSTE-ACS who meet the diagnostic criteria specified in current guideline, complicated by multivessel coronary artery disease, and have successfully undergone PCI for the culprit vessel.\n3. PCI within 72 hours of diagnosis.\n4. Accompanied by multivessel disease: defined as at least one non-culprit artery that meets the following conditions: a diameter of ≥2.5 mm by visual inspection, which can be successfully subjected to PCI, and the most severe diameter stenosis rate by visual inspection is at least 70% or positive coronary physiology testing.\n5. Sign an informed consent form before participating in the study.\n\nExclusion Criteria:\n\n1. Have received thrombolytic treatment.\n2. Cardiogenic shock or SBP\\\u003C 90 mmHg.\n3. Patients in whom the culprit vessel cannot be clearly identified.\n4. Left main coronary artery lesion, non-infarct-related arteries are CTO lesions or severely calcified lesions, complex lesions that require the use of special devices such as rotational ablation\u002Flaser.\n5. Previous PCI within the past 1 month or previous coronary artery bypass graft (CABG).\n6. Accompanied by other diseases that lead to an expected survival time of ≤ 12 months.\n7. Patients with other serious diseases such as severe renal insufficiency (creatinine clearance value \\\u003C30ml\u002Fmin), hepatic insufficiency, thrombocytopenia (≤50\\*109\u002FL).\n8. Patients with severe valvular disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension.\n9. Not suitable for clinical study:\n\n   1. Have enrolled in the other clinical studies that may affect the outcome assessment of this study.\n   2. Pregnant and lactating women.\n   3. Known allergy to the drugs that may be used in the study.\n   4. Unable to comply with the trial protocol or follow-up requirements; or the investigator believes that participation in the trial may put the patient at greater risk.","ALL","18 Years",{"count":18,"type":19},1904,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD).\n\nNSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form:\n\nIntervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing).\n\nControl group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.",[25,26,27,28],"NSTEMI","NSTEMI - Non-ST Segment Elevation MI","Non-ST-elevation Acute Coronary Syndrome","NSTE-ACS (NSTEMI and UA)",[25,30],"FUTURE II","NOT_YET_RECRUITING","2026-01-28",{"date":34,"type":35},"2026-01-30","ACTUAL",{"date":37,"type":19},"2026-02-28",{"date":39,"type":19},"2031-02-28",{"name":41,"class":42},"RenJi Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100497961","phase-3-dapagliflozine-to-attenuate-cardiac-remodeling-after-acute-myocardial-infarction-100497961","NCT05764057","DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","DAPAPROTECTOR","Inclusion Criteria:\n\n* Age ≥18 years;\n* STEMI (e.g., ST elevation above the J-point of ≥0.1 millivolt in ≥two contiguous leads or left bundle branch block) or very high-risk NSTEMI (e.g., dynamic ECG changes or ongoing chest pain or acute heart failure or hemodynamic instability independent of ECG changes or life-threatening ventricular arrhythmias) with LV dysfunction (LVEF ≤45%); after completion of PCI or angiography procedure\n* eGFR ≥ 25 mL\u002FMin per 1.73m²;\n* Systolic blood pressure (SBP) before first dosing \\>100 mmHg and\u002For Diastolic blood pressure (DBP) \\>70 mmHg before first dosing;\n* Ability to provide written informed consent and willing to participate in the 6-month follow-up period.\n* Affiliation to a national health care system (AME are not allowed).\n\nExclusion Criteria:\n\n* Cardiogenic shock (SBP \\\u003C90 mmHg with clinical signs of low output or patients requiring inotropic agents) at randomization;\n* Referred to surgery for coronary artery bypass grafting (CABG) or treatment of acute complications (e.g. ventricular septal rupture);\n* Any other form of diabetes than diabetes type 2\n* History of diabetic ketoacidosis (DKA); Known contra-indication to SGLT-2 inhibitors (hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption);\n* \\>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea;\n* Acute symptomatic urinary tract infection (UTI) or genital infection at the time of randomization;\n* Concomitant treatment (and\u002For within the 4 weeks prior to the baseline visit) with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin)\n* Echocardiographic examination of insufficient quality to permit adequate analysis of the study end-points.\n* Impossibility to evaluate cardiac remodeling using TTE (e.g., pacemaker or defibrillator …);\n* Atrial fibrillation rhythm at randomization;\n* Life expectancy \\\u003C6 month;\n* Known pregnancy at time of randomization;\n* Breastfeeding women\n* Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy)\n* Current participation in another interventional trial. Patients under guardianship or curatorship",{"count":51,"type":19},450,[53],"PHASE3","Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials evaluating the efficacy and safety of dapagliflozin (nor any other SGLT2-inhibitor) to limit cardiac remodeling in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction.\n\nPreventing cardiac remodeling, an established predictor of subsequent heart failure (HF) and cardiovascular death, is likely to translate into benefit in reducing clinical events in post-MI patients.",[56,57,25,58],"AMI","STEMI","Left Ventricular Dysfunction",[60,61,62,63,64,65],"Acute myocardial infarction","Left ventricular dysfunction","Dapagliflozin","Transthoracic echocardiography","Cardiac remodeling","Cardiovascular Intensive Care Unit (CICU)","RECRUITING","2025-12-12",{"date":69,"type":35},"2025-12-19",{"date":71,"type":35},"2023-06-12",{"date":73,"type":19},"2026-10-12",{"name":75,"class":42},"Assistance Publique - Hôpitaux de Paris",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100528871","breisgau-pheno-heart-study-100528871","NCT06166407","Breisgau Pheno Heart Study","The Breisgau Pheno Heart Study","Inclusion Criteria:\n\n* Emergency coronary angiography and age\\>18 years and STEMI or NSTEMI or \"none of these diseases\"\n\nExclusion Criteria:\n\n* Hemoglobin\\\u003C7,0 g\u002Fdl\n* Platelets \\\u003C50.000\u002Fµl\n* Unable to provide written informed consent\n* Age \\> 80 years\n* hematological neoplasia\n* metastasized cancers\n* acute infection (z.B. Sepsis)\n* Chronic Inflammatory conditions (z.B. inflammatory bowel disease, Rheumatoid arthritis, chronisch hepatitis)\n* Pregnancy\n* Immunosuppression\n* Resuscitation \\>5 min oder mehr als 1x Defibrillation vor Koronarangiographie\n* Cardiogenic shock\n* Mechanical circulatory support\n* Cardiomyopathy with an left ventricular ejection fraction F \\\u003C40% before the event\n* Dialysis\n* Cirrhosis \\> CHILD-A\n* Not living in the county of Breisgau-Hochschwarzwald or Emmendingen oder planned relocation\n* Alcohol and drug abuse\n* Non-compliance","85 Years",{"count":86,"type":19},400,"OBSERVATIONAL","Coronary heart disease and its acute complication, myocardial infarction (MI), represent the leading causes of death in Europe and the United States. Although novel treatment strategies have helped to improve survival in patients with MI, a large proportion of patients develops heart failure and is at risk of life-threatening arrhythmias. Complications arising after MI constitute a severe burden not only for the patients themselves, but also for health care systems worldwide.\n\nThe likelihood of these complications depends on the area of myocardial tissue lost and the process of myocardial repair and scar tissue formation after MI ('remodeling') which are modified by the local and systemic immune response after MI. The immune response is critical after myocardial infarction. In particular, sustained overactive and prolonged inflammatory reactions lead to accentuated myocardial damage and dysfunction. Important mediators of the inflammatory reaction after MI are monocytes, T-cells, B-cells and hematopoietic stem and progenitor cells. Following MI, myeloid cells derived from the hematopoietic system drive a sharp increase in systemic leukocyte levels that correlates closely with mortality. T- and B-cells in particular act in response to specific antigens. Most of the data regarding the inflammatory response after MI, however, are derived from animal models. The immunological phenotypes after MI and their association with clinical outcome in humans are insufficiently characterized.\n\nAims: The aim of this project is to provide establish clinically and immunologically well-characterized cohort of patients after MI This will aid in identifying novel prognostic cellular and humoral biomarkers that may be used to identify patients at a high inflammatory and immune risk and to guide clinical management. Furthermore, these mediators, in the future, may be targeted by novel antigen-specific immunomodulatory approaches.\n\nPatients with myocardial infarction (STEMI and NSTEMI) will be recruited after PCI within 24h and receive a structured follow-up. Clinical read-outs include a detailed and standardized patient history, clinical examination, standard blood work, coronary angiography, ECG, echocardiography and for subgroups, MRI. Patients will present for study visits at 6 weeks, 3 months and 12 months after the initial event. Blood will be sampled at the inclusion and during follow-up visits. Peripheral blood mononuclear cells and plasma will be stored at the Cardiovascular BioBank (CVBB) and FREEZE, both institutions at the University Hospital in Freiburg. Major adverse cardiac events (myocardial infarction, stroke, hospitalization for heart failure, cardiovascular death) will be recorded using telephone interviews and standardized queries to the local authorities. Several laboratory read-outs are planned including flow cytometry, mass cytometry, single cell RNA sequencing, T cell and B cell receptor sequencing and bulk-RNA-sequencing. In an initial approach we aim to recruit 400 patients with MI, of which we expect ≈40 to develop ischemic cardiomyopathy. Differences in immunological profiles between patients that develop MI and a propensity-matched control group will then be analyzed and correlated with clinical outcome data.",[90,57,25],"Myocardial Infarction","2023-12-12",{"date":93,"type":35},"2023-12-19",{"date":95,"type":19},"2024-04",{"date":97,"type":19},"2034-04",{"name":99,"class":42},"University Hospital Freiburg",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":76},"100438391","optimiser-registry---a-prospective-cohort-study-to-describe-the-optimal-management-and-outcomes-of-patients-presenting-with-acute-myocardial-infarction-100438391","NCT04988672","OPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction","OPTIMISER","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Individuals who are newly diagnosed with AMI or have been diagnosed with AMI (STEMI or NSTEMI) within the last 5 years (since 2016).\n* Subjects must be willing to sign a patient informed consent (PIC) OR a patient ́s relative\u002F proxy are willing to provide PIC or patients have signed the General Consent (GK).\n\nExclusion Criteria:\n\n* Patient unwilling or unable to provide informed consent\n* Patients with no ACS\u002FAMI (e.g. Takotsubo cardiomyopathy, acute heart failure not related to AMI)",{"count":108,"type":19},4000,"The purpose of the OPTIMISER Registry is to prospectively and retrospectively collect baseline, clinical and procedural data in patients who present with AMI and are treated with PCI as well as prospectively collect the clinical outcome data. Outcomes will be compared in different clinical subgroups. The impact of PCI in AMI in general as well as cardiovascular outcomes after AMI will be assessed.",[90,111,57,25],"Myocardial Ischemia","2023-10-04",{"date":114,"type":35},"2023-10-06",{"date":116,"type":35},"2021-01-01",{"date":118,"type":19},"2030-12-31",{"name":120,"class":42},"Luzerner Kantonsspital"]